Proposed Height Increase Method Legitimized For Efficacy And Safety Through Animals Studies And Testing

This is just my own personal opinion but if we should ever come up with a real method and technique to possibly increase long bone length we should have it be first tested on animals. This is always assuming that the method is invasive in any way. If it was non invasive we can all try out ideas in our own homes with store bought products.

I propose that at some point we should get into contact certain groups of medical researchers and scientists to perform our proposed method and get it written up in a real scientific journal and paper so that our cause and endeavor is taken seriously by the scientific and medical community. There is no way for us to make our cause to be heard unless we go through some red tape and beaurocracy. If we can raise a certain amount of funding, help pay for at least 1 round of researching, and get a team of university professors to test out our hypothesis, and validate it beyond statistical testing error then I believe it would be possible to really get recognition for what we are doing.

Professors throughout the world spend more than 10% of their professional lives writing up proposals for grants to get money and funding from government and corporate organizations for their interests and research. I should know since I have worked with graduate student and have done biotech and biomedical research before. The major corporations and companies like Genentech and Biogen have the equipment and resources and they also are trying to push the edge of biological science but they won’t be wiling to put their resources for a cause which is more likely to be a failure and a bad investment into this.

 

 

NeoCart Autologous Cartilage Tissue Implant For Cartilage Regrowth And Replacement

Me: I have recently found out about this product being sold called NeoCart, an autologous cartilage tissue implant, which seems to be using the technology of cartilage regrowth for eventual surgical implantation to heal fractures. What is nice about this product is that one can just buy it. To make the NeoCart product it is “produced by seeding a type-I collagen matrix scaffold with autogenous chondrocytes and bioreactor treatment“. The implications of this product and technology is that we can see that there are already places where we can buy these cartilage implants or get their services. What might be good is if we can figure out what type of growth factors were used in the bioreactor treatment along with the implanted chondrocytes. This might give us a bigger clue on how to cause induced or injected chondrocytes into bones to increase and create a cartilage layer. 

From Histogenics website HERE

Histogenics grows the NeoCart® implant ex vivo (outside the body) from the patient’s own cartilage cells in a patented, high-pressure tissue engineering processor. This processor mimics the natural conditions experienced in the knee while walking, producing more natural neocartilage than other techniques.

Phase I trials showed improvement in function and relief of pain, with 87.5 percent of subjects with good fill at 12 months, versus 50 percent of subjects with good fill who had undergone microfracture. The NeoCart Phase II trial is complete, with 6, 12 and 24-month data trends superior to the control arm microfracture.

Advantages
NeoCart implant promises an advanced solution for joint repair to help restore a patient’s active lifestyle.

  • Starts with a patient’s own cartilage cells from a simple biopsy
  • Incorporates patented 3D matrix to protect cells and encourage growth and development of cartilage tissue
  • Results in optimally produced tissue containing both multipying cells and substantial amount of true cartilage tissue
  • Is easy to handle and implant
  • Can treat large cartilage defects
  • Uses proprietary bioadhesive for strength and biocompatibility – no suturing
  • Integrates with surrounding native cartilage

Treatment
NeoCart treatment has three phases.

Cell collection.The process begins during a short, simple arthroscopic examination when an orthopedic surgeon takes a cartilage biopsy from a non-weight bearing area of the joint. The tissue biopsy is sent to the Histogenics manufacturing facility for culturing into the implant.

Tissue production. The cartilage cells, or chondrocytes, are isolated from the cartilage and multiplied using standard tissue culture techniques. The cells are harvested, seeded into a unique 3-dimensional collagen scaffold, and cultured under exacting conditions of high pressure, oxygen concentration and perfusion.

Implant. After a few weeks, a discrete three-dimensional piece of the patient’s own neocartilage, having characteristics of maturing native articular cartilage, is sent to the physician and implanted into the defect in a simple procedure that usually takes less than an hour. Within months, the matrix remodels, the cells mature, and the cartilage integrates with the host tissue.


From PubMed study link HERE

J Bone Joint Surg Am. 2012 Jun 6;94(11):979-89. doi: 10.2106/JBJS.K.00533.

NeoCart, an autologous cartilage tissue implant, compared with microfracture for treatment of distal femoral cartilage lesions: an FDA phase-II prospective, randomized clinical trial after two years.

Crawford DC, DeBerardino TM, Williams RJ 3rd.

Source

Department of Orthopaedics and Rehabilitation, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Mail Code OP31, Portland, OR 97239, USA. crawfden@ohsu.edu

Abstract

BACKGROUND:

Despite introduction of autologous chondrocyte therapy for repair of hyaline articular cartilage injury in 1994, microfracture remains a primary standard of care. NeoCart, an autologous cartilage tissue implant, was compared with microfracture in a multisite prospective, randomized trial of a tissue-engineered bioimplant for treating articular cartilage injuries in the knee.

METHODS:

Thirty patients were randomized at a ratio of two to one (two were treated with an autologous cartilage tissue implant [NeoCart] for each patient treated with microfracture) at the time of arthroscopic confirmation of an International Cartilage Repair Society (ICRS) grade-III lesion(s). Microfracture or cartilage biopsy was performed. NeoCart, produced by seeding a type-I collagen matrix scaffold with autogenous chondrocytes and bioreactor treatment, was implanted six weeks following arthroscopic cartilage biopsy. Standard evaluations were performed with validated clinical outcomes measures.

RESULTS:

Three, six, twelve, and twenty-four-month data are reported. The mean duration of follow-up (and standard deviation) was 26 ± 2 months. There were twenty-one patients in the NeoCart group and nine in the microfracture group. The mean age (40 ± 9 years), body mass index (BMI) (28 ± 4 kg/m2), duration between the first symptoms and treatment (3 ± 5 years), and lesion size (287 ± 138 mm2 in the NeoCart group and 252 ± 135 mm2 in the microfracture group) were similar between the groups. Adverse event rates per procedure did not differ between the treatment arms. The scores on the Short Form-36 (SF-36), Knee Injury and Osteoarthritis Outcome Score (KOOS) activities of daily living (ADL) scale, and International Knee Documentation Committee (IKDC) form improved from baseline (p < 0.05) to two years postoperatively in both treatment groups. In the NeoCart group, improvement, compared with baseline, was significant (p < 0.05) for all measures at six, twelve, and twenty-four months. Improvement in the NeoCart group was significantly greater (p < 0.05) than that in the microfracture group for the KOOS pain score at six, twelve, and twenty-four months; the KOOS symptom score at six months; the IKDC, KOOS sports, and visual analog scale (VAS) pain scores at twelve and twenty-four months; and the KOOS quality of life (QOL) score at twenty-four months. Analysis of covariance (ANCOVA) at one year indicated that the change in the KOOS pain (p = 0.016) and IKDC (p = 0.028) scores from pretreatment levels favored the NeoCart group. Significantly more NeoCart-treated patients (p = 0.0125) had responded to therapy (were therapeutic responders) at six months (43% versus 25% in the microfracture group) and twelve months (76% versus 22% in the microfracture group). This trend continued, as the proportion of NeoCart-treated patients (fifteen of nineteen) who were therapeutic responders at twenty-four months was greater than the proportion of microfracture-treated participants (four of nine) who were therapeutic responders at that time.

CONCLUSIONS:

This randomized study suggests that the safety of autologous cartilage tissue implantation, with use of the NeoCart technique, is similar to that of microfracture surgery and is associated with greater clinical efficacy at two years after treatment.

PMID: 22637204    [PubMed – indexed for MEDLINE]

 

How Tall Is Yao Ming? Is His Height 7′ 5″ Or 7′ 6″?

This will be another one of those fun posts which I have always wanted to write about but never could find a platform or place to write about such a topic. Today’s post is on the real height of ex-NBA star Yao Ming. Since I have been a basketball fan, I have followed the career of this Chinese Giant to see whether a person of his size would do well in professional sports. I know that he played for the Houston Rockets for his entire NBA career after being the #1 pick from the 2002 NBA Draft. When he first arrived in the US and NBA, many people did not know what to expect from this man from a foreign nation.

Now a decade later with Yao Ming retiring, the NBA has found a huge new market to go into for its newer generation of stars, China. Every month I am hearing about how basketball stars like Lebron James, Dwyane Wade, and Kobe Byrant have been coming to China to host intercultural exchange using the sport of basketball. China is getting richer and some of the best business opportunities can be found there. The people in China are also crazy about the sport from watching super human giants jump into the air and nearly fly. I remember in the 90s with the reign of Michael Jordan that the advent of the internet had not come along yet and his popularity was just starting to reach the other nations. However, the basketball players of today have found the ability to reach kids from all the countries in the world that his airness probably would not have thoughht was even possible. I am almost positive that in another 10 years, the sport of basketball will try to sink its teeth into India, Africa, Indonesia, and many other nations around the world with a large population base.

However let’s get back to seeing how tall Yao Ming really is. Some sources say he is 7’5″ but other sources say he is 7′ 6″. In SI units that means he ranges from 2.26-2.285 meters in height, at about a 2.50 cm difference. When it comes to true human giants like Yao, there heights are a real mystery for most people. It is near impossible for a person who is even 1 feet shorter than them to guess their height correctly to within 2 inches. Since we are talking about a 1 inch difference, there is no way that most other people can judge his height accurately. A person of his height can vary very quickly in weight so I will just choose the value that is found from the official NBA website which is at 310 lb (or 140.6 kg).

Other useful information about Yao from imdb.com…

His father, Yao Zhiyuan, is 6′ 7″; his mother, Fengdi Fang, is 6′ 3″ and was captain of the Chinese national women’s basketball team.

According to the Houston Rockets strength and conditioning coach, Anthony Falsone, he is still growing. Falsone says Yao was 7′ 5″ tall without shoes on (7′ 6 1/2″ with shoes) in October of 2002, but that by September of 2004, he had grown to 7′ 5 3/4″ in height barefoot, and to 7′ 7 1/4″ in height with shoes on.

At the 2004 Summer Olympic Games in Athens, Greece, he was listed as having a 7′ 5″ wingspan, a 9′ 8″ standing reach, and a size 18 shoe US.

His team media guide profile in China, stated that Yao had a 26 inch vertical leap, jumping from a standstill. However, Yao himself has said since then that two foot injuries he suffered since that time, lowered his vertical leap after this by about 4 to 6 inches.

First these are the sources that say Yao Ming is 7′ 5″ in height (2.2606 meters)

1. imdb.com  – he is actually listed at 7′ 5.5″ or 2.27 meters tall here. from the imdb link this quote is taken “According to the Houston Rockets strength and conditioning coach, Anthony Falsone, he is still growing. Falsone says Yao was 7′ 5″ tall without shoes on (7′ 6 1/2″ with shoes) in October of 2002, but that by September of 2004, he had grown to 7′ 5 3/4″ in height barefoot, and to 7′ 7 1/4″ in height with shoes on.

Me: The issue for me was that Yao came into the NBA league when he was 22, at least that was the age the Chinese government listed him as, and being able to still grow another 1 inch when one is at age 22-23 is really incredible. But then, this is a giant man with height in his genes and family so maybe he did grow.

2. Urban Dictionary – just for humor

3. CelebHeights.com – quote from site: Either gets listed at 7ft 5 or 6. Shawn Bradley, another giant of the court has been quoted as saying: “He’s not as tall as me. If he’s 7-6, I’m 7-8”. Yao has stated “I’m 7-6” before.

4. NBA Chicago Bulls Predraft Measurements – listed at 7’5″ without shoes and 7′ 6.25″ with shoes with 7′ 4.75″ wingspan.

5. USBasket.com

6. TheTallestMan.com

Next, these are the sources that say Yao Ming is 7′ 6″ in height (2.286 meters)

1. Wikipedia

2. NBA.com

3. Basketball-Reference.com

4. Yahoo! Sports

5. imdb.com – quote from the profile page: At a height of 7′ 6″, he is tied with Shawn Bradley, for the distinction of being the tallest player in the NBA.

6. HeightCeleb.info

7. TheTallestMan.com – Yao is compared to people like Hakeem Olajuwon, Michael Jordan, and Dikembe Mutombo and half of the people says he is 7′ 6″.

If you would like to do something fun, you can follow his twitter feeds HERE which is his real twitter profile.

Here is a picture I found of Yao from the 2008 Olympics Chinese Basketball Team (source HERE).

 

What I see is one of the most clear examples of Yao being at least 7′ 5″. To Yao’s right and left stands Yi Jianlian and Wang Zhizhi. While Yi Jianlian has been listed at 7’0″ in the NBA directory (HERE) his predraft measurements (HERE) show that he is actually 6′ 11″ without shoes, 7′ 0.25″ with shoes, and has a 7′ 3.5″ wingspan. On the site Asia Basketball (HERE) Yi has been listed at 2.12 meters tall which seems very reasonable since in the picture he looks almost the same height at Wang Zhizhi if not just slightly shorter.

With Wang Zhizhi he has been listed at 7′ 1″ (2.16 m) in the NBA when he first was introduced to the US but in more recent year his height is labeled at 7′ 0.25″ or 2.14 meters which seems very reasonable (Wikipedia). Other sources (HERE) list him as just 7′ 0″. Asia Basketball lists him at 2.15 meters (HERE).

With most people’s head, the tip of the top of their head to the middle level of their eye level is around 4-5 inches. For people with larger heads or larger foreheads like Yao, the top of his height to the middle of his eye level is probably 5 inches if not more. We can see that both Yi and Wang has their head below the eye level of Yao’s and probably about 1 inch  below the center of Yao’s eye level. This would definitely put Yao at the 7′ 6″ range which many basketball analyst have said about him.

As for Shawn Bradley, the ex-NBA player who has been most compared to Yao in height, Bradley was once measured on 60 minutes by Andy Rooney to have been actually 7′ 6.25″ with a rather error prone measuring tape. In most pictures of the two, Shawn does look slightly taller than Yao but maybe only by 0.25-0.5 inches at most. In the picture on the right shawn does look maybe 1 cm taller than Yao. You can clearly see the floor and their overall sneakers look about the same giving the same amount of shoe height. Their postures are about the same. They are standing relatively straight up with their back almost against each other. What is clear is that Bradley’s eye level is probably 1 inch higher than Yao’s but Yao does have a wider and thicker head than Shawn.

 

 

 

 

 

Now here is a picture of Yao with Dikembe Mutombo (source HERE) who has been listed at 7′ 2″ in his NBA career although some people have said that Dikembe was measured at 7′ 1.25″ without shoes when he first came into the League. No matter how I change the angles, Yao still looks at least 4.5-5 inches taller than Mutombo if not more. I am willing to admit that Dikembe is stnding slightly further away from the camera and his feet is at a larger angle.

 

 

 

 

 

 

 

 

 

 

 

From photo bucket (source HERE)we see on the right of Yao compared to Shaq who we have almost concluded is the 7′ 1″ height he has always claimed. From this picture we can see that Yao’s eye level is right where Shaq’s head top is. Yao’s head it slightly crooked with his neck twisting around but we can say that Yao is at least 4.5 inches taller than shaq.

From all these pictures I am going to make a final conclusion on Yao’s height. Some of the more reliable resources have always said that Yao is 7′ 5″ but the sources from the US and NBA sources say he is 7′ 6″. From my experience, I know that the NBA often pads the height of its players by at least 1 inch to make themselves look bigger. Players who were listed at 6′ 8″ goes up to 6′ 9″. What is very noticeable is that most of the player who are extremely tall like Shaq and Yao, they don’t lie or exaggerate their height since they are already tall enough. With Yao, I would say that he is probably 7′ 5.5″-7′ 5.75″ inches at the end of the night after the spinal disks have compressed. When Yao gets out of the bed in his morning, height I would guess he could be 7′ 6.25″-7.6.5″ in height. I know that for myself, my height ranges from 6’0″ when I get out of bed to 5′ 11.25″ (or even slightly lower) when I go to bed. With Yao and his body, his height should be very more varied. Since his height fluctuates so much and does probably dip down to even 7′ 5.5″ (but no lower) during the day, that was probably when the doctors made their measurements. When he was measured in the morning, he was taller. If we combine all the height variation, I would guess that Yao can be considered 7′ 6″ or just slightly less at 7′ 5.75″ than that overall since I am quite positive that he does go over the 7’6″ height limit for at least the early part of the day after waking up. That is why we can and most people do claim that Yao is 7′ 6″ tall.

A Height Increase Journal To Write Down My Research Notes

One thing I have been doing is getting a journal so I can write down notes from the research I’ve been doing. So far I have kept track of

1. Different types of growth factors on chondrogenesis and osteogenesis.

2. The dimensions and values of the mechanical and material properties of the bone in every single area.

3. The protein/hormone signaling pathway map.

4. Food and supplements which have known height increasing properties.

5. Major genes that are involved in endochondral ossification .

6. Anatomy figures of the muscles and ligaments around the bone.

How Platelet Derived Growth Factor PDGF Effects Growth And Height

Another type of growth factor which I have been noticing being mentioned a lot when looking at the regulation of the growth plate have been a group of growth factors known as Platelet Derived Growth Factor, PDGF. This post will be my attempt in doing at least some basic research on this group of growth regulation proteins. I hope that I will be able to find at least a few from the overall group that do have a critical role in growth plate regulation and chondrocyte proliferation.

First, let’s start with Wikipedia and see what it has to say about Platelet Derived Growth Factors, PDGFs….


In molecular biology, platelet-derived growth factor (PDGF) is one of the numerous growth factors, or proteins that regulate cell growth and division. In particular, it plays a significant role in blood vessel formation (angiogenesis), the growth of blood vessels from already-existing blood vessel tissue. Uncontrolled angiogenesis is a characteristic of cancer.

PDGF is a potent mitogen for cells of mesenchymal origin, including smooth muscle cells and glial cells.

Though it is synthesized stored and released by platelets upon activation, it is produced by a plethora of cells including smooth muscle cells, activated macrophages, and endothelial cells

Function

PDGFs are mitogenic during early developmental stages, driving the proliferation of undifferentiated mesenchyme and some progenitor populations. During later maturation stages, PDGF signalling has been implicated in tissue remodelling and cellular differentiation, and in inductive events involved in patterning and morphogenesis. In addition to driving mesenchymal proliferation, PDGFs have been shown to direct the migration, differentiation and function of a variety of specialised mesenchymal and migratory cell types, both during development and in the adult animal.

PDGF plays a role in embryonic development, cell proliferation, cell migration, and angiogenesis. PDGF has also been linked to several diseases such as atherosclerosis, fibrosis and malignant diseases.

PDGF is also known to maintain proliferation of oligodendrocyte progenitor cells.


Analysis & Interpretation:

From this quick definition found from Wikipedia, I would guess that the PDGFs are a group of proteins that regulate the rate at which many progenitor cells divide. The PDGF is known as a mitogen. From Wikipedia, the term mitogen refers to some external factor or compound that causes a cell to start dividing aka proliferating. If this function was applied to the focus of our research, height increase, we could say that there should be some type of mitogen, probably a PDGF that is also involved in controlling the rate at which the chondrocytes in the growth plate will divide and grow in number. The undifferentiated mesenchyme the definition is talking about can refer to the MSCs we find in the bone marrow of the intermedullary cavity of long bones.

However it seems that the PDGFs seem to work mainly on smooth muscle cells, glial cells, and oligodendrocyte progenitor cells (or a type of brain cell). What may be the most important thing to take out of this article is that the PDGFs are involved in the formation of blood vessels aka angiogenesis.

For the purposes of our desire to increase height, previous research has shown that having blood vessel disruption in the metaphyseal area of long bones may actually increase longtitudinal growth. It is important to realize that a long bone in a human body has blood vessels going in various parts of the long bone, to the ends of the bone, the epiphysis, to the middle, and to the growth plates as well.

Let’s not forget that the growth plates are cartilage, and cartilage intrinsically does not have any blood vessels going through the extracellular matric of the cartilage. The cartilage is both protected from angiogenesis and vascularization by the perichondrium (in the articular and epiphyseal cartilage) as well as angiogenesis inhibitor factors like Chondromodulin. Any “food” that the chondrocytes in the epiphyseal cartilage does get must be diffused through the matrix to it. As it should happen, when the growth plates starts getting punctured in the walls by the blood vessels, that is when the rate at which ossification and calcification of the cartilage become increased beyond the limit at which the cartilage can possibly regenerate more chondrocytes which form cartilage from the resting zone.


If we now look at the Wikipedia article on Platelet Derived Growth Factor Receptor

Platelet-derived growth factor receptors (PDGF-R) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGF-R, alpha and beta each encoded by a different gene. Depending on which growth factor is bound, PDGF-R homo- or heterodimerizes.

Interaction with signal transduction molecules

Tyrosine phosphorylation sites in growth factor receptors serve two major purposes: to control the state of activity of the kinase and to create binding sites for downstream signal transduction molecules, which in many cases also are substrates for the kinase.

Analysis & Interpretation:

We are seeing that the PDGF receptors are just like so many other receptors we have been studying and research before. They are also tyrosine kinase, which we had studied when we looked at the Wnt/Beta-Catenin Signaling pathway and the PI3K/AKT/mTOR signaling pathway. The PDGFs are just another type of growth factor then that “moves” in the extracellular fluid to eventually bind with the receptors it has on the outer cellular membrane which it would cause a cascading signal pathway. However, this type of knowledge does not tell us how exactly do this type of growth factor affect and relate to growth and overal human height.

Thus, we need to turn to studies which we might be able to find from PubMed. The first study I will turn to is “Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation.”

Endocrine. 1997 Jun;6(3):257-64.

Platelet derived growth factor stimulates chondrocyte proliferation but prevents endochondral maturation.

Kieswetter K, Schwartz Z, Alderete M, Dean DD, Boyan BD.
Source
OsteoBiologics, Inc., San Antonio, TX, USA.

Abstract

Platelet-derived growth factor (PDGF) is a cytokine released by platelets at sites of injury to promote mesenchymal cell proliferation. Since many bone wounds heal by endochondral bone formation, we examined the response of chondrocytes in the endochondral lineage to PDGF. Confluent cultures of rat costochondral resting zone cartilage cells were incubated with 0-300 ng/mL PDGF-BB for 24 h to determine whether dose-dependent changes in cell proliferation (cell number and [3H]-thymidine incorporation), alkaline phosphatase specific activity, [35S]-sulfate incorporation, or [3H]-proline incorporation into collagenase-digestible protein (CDP) or noncollagenase-digestible protein (NCP), could be observed. Long-term effects of PDGF were assessed in confluent cultures treated for 1, 2, 4, 6, 8, or 10 d with 37.5 or 150 ng/mL PDGF-BB. To determine whether PDGF-BB could induce resting zone chondrocytes to change maturation state to a growth zone chondrocyte phenotype, confluent resting zone cell cultures were treated for 1, 2, 3, or 5 d with 37.5 or 150 ng/ml PDGF-BB and then challenged for an additional 24 h with 1,25-(OH)2D3. PDGF-BB caused a dose-dependent increase in cell number and [3H]-thymidine incorporation at 24 h. The proliferative effect of the cytokine decreased with time. PDGF-BB had no effect on alkaline phosphatase at 24 h, but at later times, the cytokine prevented the normal increase in enzyme activity seen in post-confluent cultures. This effect was primarily on the cells and not on the matrix. PDGF-BB stimulated [35S]-sulfate incorporation at all times examined, but had no effect on [3H]-proline incorporation into either the CDP or NCP pools. Thus, percent collagen production was not changed. Treatment of the cells for up to 5 d with PDGF-BB failed to elicit a 1,25-(OH)2D3 responsive phenotype typical of rat costochondral growth zone cartilage cells. These results show that committed chondrocytes can respond to PDGF-BB with increased proliferation. The effect of the cytokine is to enhance cartilage matrix production, but at the same time to prevent progression of the cells along the endochondral maturation pathway.

PMID: 936868[PubMed – indexed for MEDLINE]


Analysis & Interpretation:

From Wikipedia…

Cytokines are small cell-signaling protein molecules that are secreted by numerous cells and are a category of signaling molecules used extensively in intercellular communication. Cytokines can be classified as proteins, peptides, or glycoproteins; the term “cytokine” encompasses a large and diverse family of regulators produced throughout the body by cells of diverse embryological origin. The term “cytokine” has been used to refer to the immuno modulating agents, such as interleukins and interferons. Biochemists disagree as to which molecules should be termed cytokines and which hormones.

Platelets, or thrombocytes are small, irregularly shaped clear cell fragments (i.e. cells that do not have a nucleus) which are derived from fragmentation of precursor megakaryocytes.  The average lifespan of a platelet is normally just 5 to 9 days. Platelets are a natural source of growth factors.

We learn that many wounds, which I would guess represent both skin lacerations and bone fractures, when going through the process of healing have these platelets which release the PDGF, also known as a cytokine. The researchers would take resting zone chondrocytes from the costochondral region and have them cultured and have a specific type of PDGF called PDGF-BB added to see whether the cultures will show proliferation, increased collagen production, alkaline phosphatase activity, thymidine incorporation, or  sulfate or proline incorporation. The results showed that with the PDGF-BB it seems that the initial injections did show the resting zone chondrocytes proliferate (ie. grow in number and show thymidine incorporation) but the effects over time of the PDGF decreased in effectiveness.


From 2nd PubMed study…

[Degree of differentiation of chondrocytes and their pretreatment with platelet-derived-growth factor. Regulating induction of cartilage formation in resorbable tissue carriers in vivo].

Orthopade. 2000 Feb;29(2):120-8.

[Article in German]

Lohmann CH, Schwartz Z, Niederauer GG, Boyan BD.

Source

Department of Orthopaedics, University of Texas Health Science Center, San Antonio, USA. LohmannCH@t-online.de

Abstract

Current methods for articular cartilage repair are unpredictable with respect to clinical success. In the present study, we investigated the ability of cells from articular cartilage, perichondrium, and costochondral resting zone to form new cartilage when loaded onto biodegradable scaffolds and implanted into calf muscle pouches of nu/nu mice. Prior in vitro studies showed that platelet derived growth factor-BB (PDGF-BB), but not transforming growth factor beta-1 (TGF-beta 1), basic fibroblast growth factor, or bone morphogenetic protein-2 promoted proliferation and extracellular matrix sulfation of resting zone chondrocytes without causing the cells to exhibit a hypertrophic chondrocyte phenotype. TGF-beta 1 has also been shown to stimulate chondrogenesis by multipotent chondroprogenitor cells like those in the perichondrium. In addition, PDGF-BB has been shown to modulate chondrogensis by resting zone cells implanted in poly(D,L-lactide-co-glycolide) (PLG) scaffolds. In the present study we examined whether the cartilage formation is dependent on state of chondrocyte maturation and whether the pretreatment of chondrocytes with growth factors has an influence on the cartilage formation. Scaffolds were manufactured from 80% PLG with a 75:25 lactide:glycolide ratio and 20% modified PLG with a 50:50 lactide:glycolide ratio (PLG-H scaffolds). For each experimental group, four nude mice received two identical implants, one in each calf muscle resulting in an N = 8 implants: PLG-H scaffolds alone; PLG-H scaffolds with cells derived from either the femoral articular cartilage, costochondral periochondrium, or costochondral resting zone cartilage of 125 g male Sprague-Dawley rats; PLG-H scaffolds with either articular chondrocytes or resting zone chondrocytes that were pretreated with 37.5 ng/ml rhPDGF-BB for 4 h or 24 h before implantation, or with perichondrial cells treated with PDGF-BB plus 0.22 ng/ml rhTGF beta-1 for 4 h and 24 h. At 4 or 8 weeks after implantation, samples were harvested and analyzed histomorphometrically for new cartilage formed, area of residual implant and area of fibrous connective tissue. Only resting zone cells showed the ability to form new cartilage at a heterotopic site in this study. There was no neocartilage found in nude mice with implants loaded with either articular chondrocytes or perichondrial cells. Pretreatment of resting zone chondrocytes for 4 h prior to implantation significantly increased the amount of newly formed cartilage after 8 weeks and suppressed chondrocyte hypertrophy. The amount of fibrous connective tissue around implants containing either articular chondrocytes or perichondrial cells decreased with time, whereas the amount of fibrous connective tissue around implants containing resting zone chondrocytes pretreated with PDGF-BB was increased. The results showed that resting zone cells can be successfully incorporated into biodegradable porous PLG scaffolds and can induce new cartilage formation in a nonweight-bearing site. Articular chondrocytes as well as perichondrial cells did not have the capacity for neochondrogenesis when implanted heterotopically in this model.

PMID: 10743633 [PubMed – indexed for MEDLINE]

Analysis & Interpretation:

The researchers wanted to see whether adding a certain type of growth factor into the chondrocytes which was extracted from perichondrium, resting zones, and articular cartilage and then imbedded into scafolds would result in better/ greater cartilage formation. From old results seen from other experiments on the effects of all the most well known growth factors, the TGF-Betas, the BMP-2, the bFGFs, and the PDGFs, the PDGFs seemed to be the group which could get the chondrocytes to proliferate and increase extracellular matrix sulfation without getting the chondrocytes to take the direction of mutaration into hypertrophy. The study was also going to see whether the state of the maturation of the cartilage in the scaffold would also be modulating the cartilage formation rate.

The idea was to take the PGL derived scaffold with chondrocytes embedded into them and implant the scaffold into the limbs of test animals with a growth factor treatment to see whether the growth factor which the scaffold was pretreated with will help in making new cartilage formationBesides using the PDGF-BB as the growth factor, TGF-Beta was also using as a comparison growth factor, as well as combining the two growth factors together. The results reveal that the only type of chondrocytes which showed cartilage formation were from the resting zone. The implants into the mice which were from the articular cartilage or the perichondrium showed no cartilage formation after the implantation of the scaffold/chondrocyte mix. .


Study #3: Formation of repaired hyaline cartilage using PDGF-treated chondrocyte/PCL construct in rabbit knee articular cartilage defect

From the Abstract…

Platelet derived growth factor (PDGF) has a positive mitogenic and chemotactic effect on mesenchyme derived cells, and its receptor has been identified also on chondrocytes [16]. The main reason for the usage of PDGF as a promoting factor for cartilage repair comes from the healing response in cartilage defects treated with microfracture. In this method, the formed clot in the defect site can provide an environment enriched with growth factors such as PDGF, exerting chemotactic and mitogenic effects [17]. PDGF has a direct effect on chondrocytes proliferation, differentiation and cartilage proteoglycan production and is thus believed to be able of enhancing tissue regeneration and repair [15, 16].

Although there are differences between human and animal tissues, for examining a novel treatment, a suitable animal model can be used as an important tool in enhancement of regenerative medicine. Furthermore, histological assessment of human articular cartilage after ACT is limited because biopsy for obtaining specimen may result in joint injury. In this study, we used rabbit which is a widely used animal model in study of tissue regeneration. Regarding the importance of PDGF as promoting factor for cartilage healing, we designed this study to evaluate whether PDGF is able to stimulate transplanted constructs for producing a hyaline-like repaired tissue instead of fibrocartilage one and enhance the integration of chondrocyte/PCL complex implanted in the damaged knee articular cartilage in rabbits.

Analysis & Interpretation:

It would seem that besides the many receptors found on the surface of chondrocytes, the receptor for the Platelet derived growth factor is also on it. It seems that cartilage defects from microfractures show really good results when treated with the PDGF. The interesting thing is that the abstract states explictly that the PDGF has a direct effect on chondrocyte proliferation, differentiation, and proteoglycan production. The most interesting thing that the PDGF has an effect on is that if one uses this type of growth factor on cartilage defects, the cartilage that it can produce is of the hyaline cartilage variety, not he fibrocartilage one would find. As always, the chondrocyte with the PCL scaffold matrix is used for embedding into the damaged region of cartilage in test animals/rabbits.

Short Male Babies And Adult Have Increase Risk Of Violent Suicide Attempts

Me: I found this study which linked to small babies to adult suicide rates to be very interesting. The biological answer that is stated is over the fact that smaller babies haveve less serotonin, which contributes to impulsivity, agression, and suicidal behavior. It seems babies which are born either shorter or lighter than their counter parts are both at risk to suicide. However, that is not all. Short stature in adulthood also increased the suicide tendency, which makes perfect sense, where they were smaller as a baby or average as a baby. It seems no matter how we view it, smaller people just have higher rates of suicide attempts. Obviously there is a social and emotional challenge associated with small stature and I believe completely that anyone who has insecurities with their small stature should seek comfort and help from someone to reduce the risks of suicidal behavior.

From Science Daily

Short Male Babies Have More Than Double The Risk Of Violent Suicide Attempts, Study Suggests

ScienceDaily (Jan. 18, 2008) — Short male babies run more than double the risk of a violent suicide attempt as an adult, suggests a new study. Catch up growth during childhood does not lessen the impact of short stature at birth, the research shows.

(Me: That is very interesting that catch-up growth seems to have no effect so it is more than just social or emotional but biological in nature)

The findings are based on almost 320,000 Swedish men out of a total of more than 713,000 people all born between 1973 and 1980. Using national registers, they were tracked from birth to the date of attempted suicide, death, emigration, or the end of 1999, whichever came first.

Short babies of less than 47 cm in length, were more likely to attempt suicide as adults, no matter what height they reached in adulthood, compared with normal length babies. Short birth length also more than doubled the risk of a violent suicide attempt as opposed to a non-violent one.

A violent suicide attempt was defined as hanging, the use of a firearm or knives, jumping from a height or in front of vehicles, and drowning.

Short stature in adulthood also boosted the risk.

Men who were normal length babies, but who were short in adult life were 56% more likely than tall men to attempt to take their own lives. The taller a man was, the less likely he was to attempt suicide, the findings showed.

Men who were born underweight (under 2500 g), but who reached normal height were more than 2.5 times as likely to make a violent suicide attempt.

And those who were born prematurely, and therefore short and underweight, were more than four times as likely to attempt violent suicide as those born after 38 to 40 weeks of pregnancy.

The authors suggest that the brain chemical serotonin may be key. It is crucial to brain development and low levels are important in impulsivity, aggression, and suicidal behaviour. Serotonin levels may be affected by premature birth and other factors restricting growth in the womb, they add.

This study, Fetal and childhood growth and the risk of violent and non-violent suicide attempts: A cohort study of 318,953 men, is published in the Journal of Epidemiology and Community Health.